Terazosin
Alpha-1 adrenergic blocker (non-selective), Benign prostatic hyperplasia treatment, Antihypertensive
Terazosin
Hytrin (US brand discontinued); mostly generic
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Benign prostatic hyperplasia (LUTS)0, Hypertension (later-line)0
Pharmacy
Starting dose
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg
Preparations
1, 2, 5, 10 mg capsules and tablets
US FDA Max
20 mg/d
Pharmacology
Routes
Oral
Onset
BP and symptomatic LUTS improvement within 1-2 weeks
Duration
24 hours
Half-life
~12 hours[1]
Bioavailability
>90% (oral; not significantly affected by food)[1]
Pregnancy
Limited data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Terazosin is a non-selective α1 adrenergic receptor antagonist that relaxes vascular smooth muscle (lowering BP) and prostatic/bladder-neck smooth muscle (improving urodynamic flow); like doxazosin, it lacks α1A subtype selectivity, producing more peripheral hypotension than tamsulosin and the characteristic first-dose syncope that drives bedtime initiation.0 Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, terazosin HCl, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019057s032lbl.pdf